Gene Expression Profile as a Predictor of Seizure Liability
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24044116 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anssi Lipponen und 6 weiteren Autor:innen. Beteiligte Einrichtung: A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative, Academy of Finland, The Sigrid Juselius Foundation.
Abstract (Originalsprache)
Analysis platforms to predict drug-induced seizure liability at an early phase of drug development would improve safety and reduce attrition and the high cost of drug development. We hypothesized that a drug-induced in vitro transcriptomics signature predicts its ictogenicity. We exposed rat cortical neuronal cultures to non-toxic concentrations of 34 compounds for 24 h; 11 were known to be ictogenic (tool compounds), 13 were associated with a high number of seizure-related adverse event reports in the clinical FDA Adverse Event Reporting System (FAERS) database and systematic literature search (FAERS-positive compounds), and 10 were known to be non-ictogenic (FAERS-negative compounds). The drug-induced gene expression profile was assessed from RNA-sequencing data. Transcriptomics profiles induced by the tool, FAERS-positive and FAERS-negative compounds, were compared using bioinformatics and machine learning. Of the 13 FAERS-positive compounds, 11 induced significant differential gene expression; 10 of the 11 showed an overall high similarity to the profile of at least one tool compound, correctly predicting the ictogenicity. Alikeness-% based on the number of the same differentially expressed genes correctly categorized 85%, the Gene Set Enrichment Analysis score correctly categorized 73%, and the machine-learning approach correctly categorized 91% of the FAERS-positive compounds with reported seizure liability currently in clinical use. Our data suggest that the drug-induced gene expression profile could be used as a predictive biomarker for seizure liability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland.
- Expert Microbiology Unit, Finnish Institute for Health and Welfare, P.O. Box 95, FIN-70701 Kuopio, Finland.
- Institute of Biomedicine, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland.
ORCID-Profile: Anssi Lipponen, Mikko Hiltunen, Asla Pitkänen
Förderung
- Innovative Medicines Initiative
- Academy of Finland
- The Sigrid Juselius Foundation
- The Strategic Neuroscience Funding of the University of Eastern Finland
Zitieren
APA
Lipponen, A., Kajevu, N., Natunen, T., Ciszek, R., Puhakka, N., Hiltunen, M., & Pitkänen, A. (2023). Gene Expression Profile as a Predictor of Seizure Liability. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044116
Vancouver
Lipponen A, Kajevu N, Natunen T, Ciszek R, Puhakka N, Hiltunen M, et al. Gene Expression Profile as a Predictor of Seizure Liability. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24044116
BibTeX
@article{Lipponen2023,
author = {Lipponen, Anssi and Kajevu, Natallie and Natunen, Teemu and Ciszek, Robert and Puhakka, Noora and Hiltunen, Mikko and Pitkänen, Asla},
title = {Gene Expression Profile as a Predictor of Seizure Liability},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24044116}
}
EUVIMED